ALK-Abello rises as 2nd-qtr revenues grow more than 40%

16 August 2016

Shares of Danish allergy specialist ALK-Abello (ALKB: DC) moved up 3.0% to 960 Danish kroner by early afternoon, following the company’s announcement of second-quarter 2016 results showing strong sales and earnings growth.

Total revenue for the quarter, including partner income, grew organically by 41% to 773 million kroner ($116.2 million).Revenue in the base business grew organically by 43% to 762 million kroner.

Operating profit (earnings before interest, taxes, depreciation and amortization; EBITDA) in the second quarter was 159 million kroner and the EBITDA margin was 21% (2%). EBITDA before special items was 167 million kroner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK